

The Centers for Medicare & Medicaid Services' Office of Research, Development, and Information (ORDI) strives to make information available to all. Nevertheless, portions of our files including charts, tables, and graphics may be difficult to read using assistive technology.

Persons with disabilities experiencing problems accessing portions of any file should contact ORDI through e-mail at [ORDI\\_508\\_Compliance@cms.hhs.gov](mailto:ORDI_508_Compliance@cms.hhs.gov).

**STATISTICAL COMPENDIUM:  
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT IN 2005  
ALASKA**

**LIST OF TABLES**

**OVERVIEW OF STUDY POPULATION**

TABLE 1. OVERVIEW OF BENEFICIARY SELECTION CRITERIA FOR STUDY POPULATION

**FOR ALL MEDICAID BENEFICIARIES**

TABLE 2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE 3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE 4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE 5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC

TABLE 6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE 7. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

**FOR ALL NONDUAL BENEFICIARIES**

TABLE ND.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE ND.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE ND.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE ND.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE ND.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE ND.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE ND.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE ND.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE ND.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
BY TOP 10 DRUG GROUP

TABLE ND.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS, BY  
BENEFICIARY CHARACTERISTIC

TABLE ND.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG NONDUALS PER BENEFIT MONTH,  
BY BENEFICIARY CHARACTERISTIC

TABLE ND.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES  
AMONG NONDUALS

**FOR DUAL ELIGIBLE BENEFICIARIES**

TABLE D.2. CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY

TABLE D.3. ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC

TABLE D.4. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC

TABLE D.5. AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND

BENEFICIARY CHARACTERISTIC

TABLE D.6. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY

TABLE D.7-7D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP

TABLE D.8. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BENEFICIARY CHARACTERISTIC

TABLE D.9. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS, BY BRAND STATUS AND

THERAPEUTIC CATEGORY

TABLE D.10-10D. MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
BY TOP 10 DRUG GROUP

TABLE D.11. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS, BY BENEFICIARY CHARACTERISTIC

TABLE D.12. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D AMONG DUALS PER BENEFIT MONTH, BY

BENEFICIARY CHARACTERISTIC

TABLE D.13. USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG DUALS

**SUPPLEMENTAL TABLES**

SUPPLEMENTAL TABLE 1. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES

SUPPLEMENTAL TABLE 1A. MEDICAID PHARMACY REIMBURSEMENT FOR DISABLED DUAL ELIGIBLE BENEFICIARIES UNDER AGE 65

SUPPLEMENTAL TABLE 1B. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 AND OLDER

SUPPLEMENTAL TABLE 1C. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 65 TO 74

SUPPLEMENTAL TABLE 1D. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 75 TO 84

SUPPLEMENTAL TABLE 1E. MEDICAID PHARMACY REIMBURSEMENT FOR DUAL ELIGIBLE BENEFICIARIES AGE 85 AND OLDER

**APPENDIX TABLES**

APPENDIX TABLE A.1. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS  
OF ELIGIBILITY, NONDUAL BENEFICIARIES

APPENDIX TABLE A.2. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, NONDUAL BENEFICIARIES  
APPENDIX TABLE A.3. CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY, DUAL ELIGIBLE BENEFICIARIES  
APPENDIX TABLE A.4. MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS, DUAL ELIGIBLE BENEFICIARIES

TABLE ND.2  
CHARACTERISTICS OF MEDICAID STUDY POPULATION BENEFICIARIES, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Disabled	Adults	Children	Other/ Unknown	All	Aged	Disabled	Adults	Children	Other/ Unknown
<b>All</b>	<b>119,692</b>	<b>808</b>	<b>8,318</b>	<b>28,091</b>	<b>82,317</b>	<b>158</b>	<b>1,019,186</b>	<b>8,184</b>	<b>85,310</b>	<b>199,032</b>	<b>725,664</b>	<b>996</b>
<b>Age</b>												
5 and younger	31,642	0	445	0	31,197	0	267,697	0	4,234	0	263,463	0
6-14	37,239	0	862	4	36,373	0	344,850	0	9,481	29	335,340	0
15-20	20,289	0	731	5,039	14,514	5	169,027	0	7,616	35,608	125,792	11
21-44	22,915	0	2,444	20,142	233	96	166,534	0	25,417	139,547	1,069	501
45-64	6,676	15	3,703	2,902	0	56	61,682	143	37,251	23,808	0	480
65-74	535	403	127	4	0	1	5,329	4,033	1,252	40	0	4
75-84	317	311	6	0	0	0	3,354	3,295	59	0	0	0
85 and older	79	79	0	0	0	0	713	713	0	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
<b>Gender</b>												
Female	65,896	523	4,159	20,962	40,094	158	551,612	5,457	43,568	146,772	354,819	996
Male	53,793	285	4,159	7,129	42,220	0	467,550	2,727	41,742	52,260	370,821	0
Unknown	3	0	0	0	3	0	24	0	0	0	24	0
<b>Race</b>												
White	48,376	157	4,407	12,204	31,481	127	404,430	1,419	44,823	83,951	273,452	785
African American	6,483	17	506	1,393	4,563	4	55,935	151	5,072	9,919	40,764	29
Other/unknown	64,833	634	3,405	14,494	46,273	27	558,821	6,614	35,415	105,162	411,448	182
<b>Use of Nursing Facilities<sup>c</sup></b>												
Entire year	71	16	55	0	0	0	665	156	509	0	0	0
Part year	97	12	79	5	1	0	911	107	755	44	5	0
None	119,524	780	8,184	28,086	82,316	158	1,017,610	7,921	84,046	198,988	725,659	996
<b>Maintenance Assistance Status</b>												
Cash	41,454	777	7,552	16,065	17,060	0	367,483	7,938	77,573	126,362	155,610	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty-related	65,734	0	0	9,905	55,671	158	537,346	0	0	56,613	479,737	996
Other/unknown	12,504	31	766	2,121	9,586	0	114,357	246	7,737	16,057	90,317	0
<b>Managed Care (MC) Status</b>												
Fee-for-service (FFS) all year	119,692	808	8,318	28,091	82,317	158	1,019,186	8,184	85,310	199,032	725,664	996
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.2 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; Rx = pharmacy benefit.

TABLE ND.3  
ANNUAL MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFICIARY, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	Percentage with at Least One Rx	Mean Number of Rx	Mean Rx \$	\$ per Rx	Mean \$, All Medicaid FFS \$ <sup>c</sup>	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>d</sup>	Number of Beneficiaries
<b>All</b>	<b>54.4</b>	<b>7.1</b>	<b>\$567</b>	<b>\$80</b>	<b>\$5,958</b>	<b>9.5</b>	<b>119,692</b>
<b>Age</b>							
5 and younger	53.5	2.4	181	76	4,638	3.9	31,642
6-14	43.8	2.9	269	92	3,374	8.0	37,239
15-20	53.2	4.6	538	116	7,118	7.6	20,289
21-44	66.7	11.3	842	75	7,517	11.2	22,915
45-64	75.9	40.8	2,977	73	15,863	18.8	6,676
65-74	81.9	38.8	2,175	56	17,628	12.3	535
75-84	85.2	40.3	2,168	54	22,063	9.8	317
85 and older	75.9	42.4	2,105	50	21,995	9.6	79
Unknown	0.0	0.0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>e</sup></b>							
Aged	82.2	38.3	2,129	56	19,075	11.2	808
Disabled	80.8	46.6	4,091	88	27,685	14.8	8,318
Adults	63.9	7.2	445	62	5,012	8.9	28,091
Children	48.3	2.7	233	85	3,938	5.9	82,317
Unknown	63.3	15.7	2,456	156	15,879	15.5	158
<b>Gender</b>							
Female	58.3	8.2	571	70	6,043	9.5	65,896
Male	49.7	5.7	561	98	5,855	9.6	53,793
Unknown	33.3	0.3	80	239	343	23.2	3
<b>Race</b>							
White	58.2	9.1	776	85	5,815	13.3	48,376
African American	55.1	8.4	673	80	5,157	13.1	6,483
Other/unknown	51.6	5.4	400	74	6,145	6.5	64,833
<b>Use of Nursing Facilities<sup>f</sup></b>							
Entire year	95.8	83.5	7,044	84	123,944	5.7	71
Part year	95.9	88.4	6,326	72	100,724	6.3	97
None	54.4	7.0	558	80	5,811	9.6	119,524
<b>Maintenance Assistance Status</b>							
Cash	61.0	14.2	1,098	77	8,282	13.3	41,454
Medically needy	0.0	0.0	0	0	0	0.0	0
Poverty related	49.6	2.7	197	74	4,024	4.9	65,734
Other/unknown	58.1	6.7	751	113	8,421	8.9	12,504

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.3 includes beneficiaries represented by Cell K of Table 1.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.4  
MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	Mean Number of Rx	Mean Rx \$	Rx \$ as a Percentage of All Medicaid FFS \$ <sup>c</sup>	Number of Rx, Percentage with:						Mean \$, All Medicaid FFS \$ <sup>d</sup>	Number	
				None	More than 0, but 1 or Less	More than 1, but 2 or Less	More than 2, but 5 or Less	More than 5, but 10 or Less	More than 10		Beneficiaries	Benefit Months
<b>All</b>	<b>0.8</b>	<b>\$67</b>	<b>9.5</b>	<b>45.6</b>	<b>43.3</b>	<b>4.5</b>	<b>4.1</b>	<b>1.6</b>	<b>0.9</b>	<b>\$700</b>	<b>119,692</b>	<b>1,019,186</b>
<b>Age</b>												
5 and younger	0.3	21	3.9	46.5	50.7	2.0	0.7	0.0	0.0	548	31,642	267,697
6-14	0.3	29	8.0	56.2	39.5	2.4	1.6	0.2	0.1	364	37,239	344,850
15-20	0.6	65	7.6	46.8	44.2	4.8	3.2	0.7	0.3	854	20,289	169,027
21-44	1.6	116	11.2	33.3	44.4	9.1	8.7	3.1	1.3	1,034	22,915	166,534
45-64	4.4	322	18.8	24.1	25.7	10.3	18.8	12.6	8.5	1,717	6,676	61,682
65-74	3.9	218	12.3	18.1	26.2	13.8	24.9	10.8	6.2	1,770	535	5,329
75-84	3.8	205	9.8	14.8	26.8	13.6	24.6	12.9	7.3	2,085	317	3,354
85 and older	4.7	233	9.6	24.1	19.0	11.4	24.1	16.5	5.1	2,437	79	713
Unknown	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
<b>Basis of Eligibility<sup>e</sup></b>												
Aged	3.8	210	11.2	17.8	26.1	13.5	24.4	12.4	5.8	1,883	808	8,184
Disabled	4.5	399	14.8	19.2	27.0	11.1	19.9	13.0	9.9	2,699	8,318	85,310
Adults	1.0	63	8.9	36.1	45.9	8.4	7.2	2.0	0.4	707	28,091	199,032
Children	0.3	27	5.9	51.7	44.3	2.4	1.3	0.2	0.1	447	82,317	725,664
Unknown	2.5	390	15.5	36.7	31.0	11.4	13.9	5.7	1.3	2,519	158	996
<b>Gender</b>												
Female	1.0	68	9.5	41.7	45.3	5.3	4.8	2.0	1.0	722	65,896	551,612
Male	0.7	65	9.6	50.3	40.9	3.6	3.4	1.1	0.7	674	53,793	467,550
Unknown	0.0	10	23.2	66.7	33.3	0.0	0.0	0.0	0.0	43	3	24
<b>Race</b>												
White	1.1	93	13.3	41.8	43.5	5.6	5.5	2.3	1.2	696	48,376	404,430
African American	1.0	78	13.1	44.9	43.8	4.8	4.0	1.2	1.2	598	6,483	55,935
Other/unknown	0.6	46	6.5	48.4	43.1	3.6	3.1	1.1	0.6	713	64,833	558,821
<b>Use of Nursing Facilities<sup>f</sup></b>												
Entire year	8.9	752	5.7	4.2	4.2	1.4	29.6	33.8	26.8	13,233	71	665
Part year	9.4	674	6.3	4.1	9.3	7.2	19.6	27.8	32.0	10,725	97	911
None	0.8	66	9.6	45.6	43.4	4.5	4.1	1.6	0.8	683	119,524	1,017,610
<b>Maintenance Assistance Status</b>												
Cash	1.6	124	13.3	39.0	40.2	6.6	8.2	3.9	2.2	934	41,454	367,483
Medically needy	0.0	0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0	0	0
Poverty related	0.3	24	4.9	50.4	44.9	2.9	1.5	0.2	0.1	492	65,734	537,346
Other/unknown	0.7	82	8.9	41.9	45.5	5.9	4.8	1.2	0.6	921	12,504	114,357

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.4 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the expenditures in this column include only Rx drug expenditures for those enrolled in capitated managed care plans, and not expenditures for other services covered by the plans or long-term-care services not covered by the plans. As a result, the amounts shown in this column for all Medicaid fee-for-service expenditures are lower than they would otherwise be.

d. In eight states (DE, IA, IL, NE, NY, TX, UT, and WV) the Rx share of expenditures for all Medicaid services shown in this column is higher than it would be if all expenditures for these other services, including services provided in capitated managed care plans and long-term-care services, were included.

e. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

f. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.5  
AVERAGE MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH, BY BRAND STATUS AND BENEFICIARY CHARACTERISTIC<sup>a, b, c</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	All Rx			Patented Brand-Name Drugs			Off-Patent Brand-Name Drugs			Generic Drugs		
	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx	Number of Rx	Rx \$	\$ per Rx
<b>All</b>	<b>0.8</b>	<b>\$67</b>	<b>\$80</b>	<b>0.3</b>	<b>\$50</b>	<b>\$150</b>	<b>0.0</b>	<b>\$4</b>	<b>\$82</b>	<b>0.4</b>	<b>\$12</b>	<b>\$28</b>
<b>Age</b>												
5 and younger	0.3	21	76	0.1	17	177	0.0	1	53	0.2	4	21
6-14	0.3	29	92	0.2	24	150	0.0	1	73	0.1	4	26
15-20	0.6	65	116	0.2	55	233	0.0	3	68	0.3	7	26
21-44	1.6	116	75	0.5	82	149	0.1	7	85	0.9	26	29
45-64	4.4	322	73	1.8	225	124	0.2	25	104	2.4	72	31
65-74	3.9	218	56	1.6	155	96	0.2	9	47	2.1	54	26
75-84	3.8	205	54	1.7	150	90	0.2	9	44	1.9	46	24
85 and older	4.7	233	50	2.0	165	82	0.3	11	33	2.3	57	24
Unknown	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
<b>Basis of Eligibility<sup>d</sup></b>												
Aged	3.8	210	56	1.6	151	94	0.2	9	45	2.0	50	26
Disabled	4.5	399	88	2.0	304	150	0.2	24	96	2.3	71	31
Adults	1.0	63	62	0.3	40	140	0.1	5	87	0.7	18	26
Children	0.3	27	85	0.1	22	162	0.0	1	62	0.2	4	23
Unknown	2.5	390	156	1.0	328	328	0.2	17	94	1.3	38	29
<b>Gender</b>												
Female	1.0	68	70	0.4	49	131	0.1	4	79	0.5	15	27
Male	0.7	65	98	0.3	52	180	0.0	3	87	0.3	10	29
Unknown	0.0	10	239	0.0	10	239	0.0	0	0	0.0	0	0
<b>Race</b>												
White	1.1	93	85	0.5	70	150	0.1	6	100	0.6	17	30
African American	1.0	78	80	0.4	63	145	0.0	3	71	0.5	12	24
Other/unknown	0.6	46	74	0.2	34	152	0.0	3	66	0.4	9	26
<b>Use of Nursing Facilities<sup>e</sup></b>												
Entire year	8.9	752	84	2.9	476	167	0.7	56	85	5.3	217	41
Part year	9.4	674	72	3.6	474	133	0.5	39	77	5.3	156	30
None	0.8	66	80	0.3	50	150	0.0	4	82	0.4	12	28
<b>Maintenance Assistance Status</b>												
Cash	1.6	124	77	0.6	90	142	0.1	8	92	0.9	26	29
Medically needy	0.0	0	0	0.0	0	0	0.0	0	0	0.0	0	0
Poverty related	0.3	24	74	0.1	19	148	0.0	1	62	0.2	4	23
Other/unknown	0.7	82	113	0.3	70	204	0.0	3	69	0.3	9	27

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.5 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. The Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 2.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

e. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.6  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Therapeutic Category	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users <sup>e</sup>				
	Total	Off-Brand-Name		Generic	Total	Off-Brand-Name		Generic	Total	Off-Brand-Name		Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All Benes	Number of Benefit Months
		Patented	Patent			Patented	Patent			Patented	Patent						
Anti-infective Agents	0.2	0.1	0.0	0.2	\$14	\$8	\$2	\$4	\$61	\$141	\$77	\$28	93,084	\$5,679,773	40,344	33.7	394,358
Biologicals	0.5	0.5	0.0	0.0	667	667	0	0	1406	1,408	0	70	1,779	2,501,098	422	0.4	3,750
Antineoplastic Agents	0.6	0.1	0.0	0.4	179	148	8	23	320	989	345	60	2,690	860,099	467	0.4	4,797
Endocrine/Metabolic Drugs	0.6	0.2	0.1	0.3	32	19	6	7	56	95	57	25	67,810	3,812,051	12,749	10.7	120,830
Cardiovascular Agents	1.4	0.5	0.0	0.8	57	41	1	14	41	76	40	17	95,069	3,850,673	6,622	5.5	67,551
Respiratory Agents	0.4	0.2	0.0	0.2	26	22	1	3	67	103	71	19	79,205	5,332,930	20,263	16.9	202,280
Gastrointestinal Agents	0.6	0.3	0.0	0.2	65	54	1	10	113	156	69	47	46,789	5,273,612	8,103	6.8	80,654
Genitourinary Agents	0.3	0.1	0.0	0.1	16	11	2	3	54	73	63	29	9,993	543,438	3,631	3.0	34,211
CNS Drugs	1.3	0.7	0.0	0.5	127	109	2	15	99	151	89	29	161,462	15,972,192	12,802	10.7	125,942
Stimulants/Anti-obesity/Anorexia	0.7	0.6	0.0	0.1	76	69	1	5	109	125	86	43	24,506	2,676,834	3,420	2.9	35,320
Miscellaneous Psychological/Neurological Agents	0.9	0.9	0.0	0.0	246	246	0	0	287	287	0	19	1,958	561,401	214	0.2	2,282
Analgesics and Anesthetics	0.5	0.1	0.0	0.4	29	12	5	12	59	202	235	29	107,514	6,334,710	23,253	19.4	220,385
Neuromuscular Agents	0.9	0.4	0.1	0.5	73	47	4	21	77	126	70	41	73,484	5,625,904	7,676	6.4	77,592
Nutritional Products	0.4	0.0	0.0	0.3	7	1	1	5	17	30	17	16	17,197	285,801	4,916	4.1	43,603
Hematological Agents	0.7	0.3	0.1	0.3	387	379	3	5	521	1,424	26	14	10,589	5,521,793	1,451	1.2	14,254
Topical Products	0.2	0.1	0.0	0.1	11	6	0	4	50	103	57	26	48,633	2,446,523	23,441	19.6	232,456
Miscellaneous Products	0.2	0.1	0.0	0.0	21	16	1	3	122	123	191	106	3,975	486,782	2,267	1.9	23,069
Unknown Therapeutic Category	0.2	0.0	0.0	0.0	14	0	0	0	74	0	0	0	965	71,217	514	0.4	5,076
<b>TOTAL NO. OF RX AND RX \$</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>846,702</b>	<b>67,836,831</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.6 includes the beneficiaries represented by Cell K of Table 1. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

d. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. In Alaska, 2.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined. For information about this classification method, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries



TABLE ND.7  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT, BY TOP 10 DRUG GROUP<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Top 10 Drug Groups	Users			Among Users			
	Total Medicaid Rx \$	Number of Users	As a Percentage of All Beneficiaries	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$10,460,824	5,199	4.3	55,431	1.0	\$183	\$189
ANTICONVULSANT	4,844,752	4,688	3.9	49,663	1.0	101	98
MISC. HEMATOLOGICAL	4,467,391	292	0.2	3,134	1.0	1,452	1,425
ANTIDEPRESSANTS	4,309,987	10,821	9.0	109,105	0.7	58	40
ANALGESICS - Narcotic	4,061,446	24,659	20.6	238,679	0.3	55	17
ULCER DRUGS	3,465,414	6,869	5.7	69,368	0.5	99	50
ANTIASTHMATIC	3,436,291	18,207	15.2	185,221	0.3	72	19
STIMULANTS/ANTI-OBESITY/ANOREXIANTS	2,676,834	3,912	3.3	40,979	0.6	109	65
PASSIVE IMMUNIZING AGENTS	2,498,566	393	0.3	3,473	0.5	1,424	719
DERMATOLOGICAL	1,659,910	18,634	15.6	188,417	0.2	57	9
Total	41,881,415	93,674		943,470	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7 includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED  
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTICONVULSANT				
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
All	393,904	\$41,881,415	5,199	4.3	55,431	1.0	\$189	4,688	3.9	49,663	1.0	\$98
Female												
All Females	237,702	20,763,101	2,717	4.1	28,676	1.0	162	2,873	4.4	30,219	0.9	95
Female, Disabled												
All Ages	113,934	10,950,776	1,260	30.3	14,274	1.4	225	1,378	33.1	15,446	1.3	123
5 and younger	805	296,983	1	0.5	12	0.8	109	11	5.7	127	0.8	259
6-14	2,755	394,709	61	21.9	714	0.8	175	83	29.7	966	1.0	189
15-20	3,246	447,504	78	28.8	876	0.9	178	82	30.3	919	1.0	182
21-44	38,555	3,666,690	502	38.4	5,702	1.4	231	523	40.0	5,824	1.4	130
45-64	67,078	6,034,114	600	29.6	6,780	1.5	235	669	33.0	7,501	1.2	101
65-74	1,467	107,911	18	24.0	190	1.1	148	10	13.3	109	1.1	60
75-84	28	2,865	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
Female, Other Eligibles												
All Ages	123,768	9,812,325	1,457	2.4	14,402	0.6	99	1,495	2.4	14,773	0.6	66
5 and younger	10,309	1,326,848	17	0.1	190	0.4	60	45	0.3	429	0.4	74
6-14	19,499	1,653,237	290	1.6	3,076	0.7	138	192	1.1	2,018	0.9	92
15-20	22,029	1,712,111	471	4.4	4,717	0.6	107	279	2.6	2,702	0.7	81
21-44	54,933	3,752,034	561	3.5	5,250	0.4	68	790	4.9	7,654	0.5	54
45-64	11,749	979,742	89	5.2	901	0.5	95	164	9.6	1,702	0.5	61
65-74	2,605	204,280	11	4.4	111	1.8	174	15	6.0	168	1.2	79
75-84	2,256	158,964	12	5.6	109	1.6	149	9	4.2	88	1.3	40
85 and older	388	25,109	6	11.5	48	1.4	103	1	1.9	12	0.1	2
Male												
All Males	156,202	21,118,314	2,482	4.6	26,755	1.1	218	1,815	3.4	19,444	1.0	101
Male, Disabled												
All Ages	75,584	10,220,714	1,294	31.1	14,268	1.4	272	1,007	24.2	11,214	1.3	123
5 and younger	1,273	351,392	5	2.0	54	0.8	149	36	14.2	401	0.9	117
6-14	7,522	1,214,782	203	34.8	2,373	0.9	203	159	27.3	1,844	1.0	133
15-20	6,272	2,138,657	182	39.6	2,014	1.1	222	120	26.1	1,312	1.0	145
21-44	24,447	3,043,910	559	49.2	6,096	1.5	309	335	29.5	3,773	1.4	128
45-64	34,980	3,408,133	338	20.2	3,658	1.6	285	348	20.8	3,786	1.3	108
65-74	1,074	61,800	7	13.5	73	3.1	229	9	17.3	98	2.2	77
75-84	16	2,040	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Beneficiaries

TABLE ND.7A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS COMBINED  
 AND FIRST AND SECOND GROUPS SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTICONVULSANT				
	Number of Rx	Rx \$	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>Male, Other Eligibles</b>												
All Ages	80,618	10,897,600	1,188	2.4	12,487	0.7	156	808	1.6	8,230	0.7	72
5 and younger	13,288	1,816,797	24	0.1	230	0.5	89	55	0.3	554	0.4	69
6-14	31,465	3,808,525	598	3.2	6,600	0.8	168	296	1.6	3,167	0.8	72
15-20	19,327	4,058,824	433	4.8	4,473	0.8	159	221	2.5	2,271	0.8	90
21-44	9,552	680,217	94	2.1	785	0.4	69	146	3.3	1,331	0.4	56
45-64	4,334	328,861	25	2.0	240	0.4	57	73	5.8	723	0.5	56
65-74	1,299	107,644	5	3.2	60	0.8	359	10	6.4	108	0.8	34
75-84	765	70,301	6	6.2	64	0.6	96	7	7.2	76	0.7	24
85 and older	588	26,431	3	11.1	35	2.8	128	0	0.0	0	0.0	0
<b>Unknown</b>	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7A includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	MISC. HEMATOLOGICAL					ANTIDEPRESSANTS					ANALGESICS - Narcotic				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>All</b>	<b>292</b>	<b>0.2</b>	<b>3,134</b>	<b>1.0</b>	<b>\$1,426</b>	<b>10,821</b>	<b>9.0</b>	<b>109,105</b>	<b>0.7</b>	<b>\$40</b>	<b>24,659</b>	<b>20.6</b>	<b>238,679</b>	<b>0.3</b>	<b>\$17</b>
<b>Female</b>															
All Females	165	0.3	1,792	1.1	95	7,861	11.9	78,605	0.7	39	16,961	25.7	162,748	0.3	17
<b>Female, Disabled</b>															
All Ages	114	2.7	1,250	1.1	100	2,530	60.8	28,186	1.0	54	3,236	77.8	36,442	0.5	40
5 and younger	1	0.5	12	0.1	6	1	0.5	12	0.8	10	27	14.1	306	0.1	1
6-14	0	0.0	0	0.0	0	40	14.3	464	0.6	28	41	14.7	469	0.1	2
15-20	0	0.0	0	0.0	0	88	32.5	933	0.6	40	79	29.2	859	0.2	3
21-44	15	1.1	171	1.5	94	877	67.1	9,830	1.0	53	1,103	84.4	12,541	0.4	38
45-64	95	4.7	1,031	1.0	101	1,492	73.5	16,627	1.0	56	1,950	96.1	21,851	0.5	45
65-74	3	4.0	36	2.4	130	31	41.3	308	1.0	47	34	45.3	392	0.4	14
75-84	0	0.0	0	0.0	0	1	20.0	12	0.9	84	2	40.0	24	0.1	2
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Female, Other Eligibles</b>															
All Ages	51	0.1	542	0.9	83	5,331	8.6	50,419	0.5	31	13,725	22.2	126,306	0.3	10
5 and younger	0	0.0	0	0.0	0	14	0.1	154	0.2	15	418	2.8	4,308	0.1	1
6-14	0	0.0	0	0.0	0	363	2.0	3,788	0.6	29	1,109	6.3	11,477	0.1	2
15-20	0	0.0	0	0.0	0	1,097	10.3	10,606	0.5	31	2,762	26.0	25,356	0.2	3
21-44	13	0.1	127	0.4	47	3,156	19.6	28,819	0.4	31	8,271	51.4	73,403	0.3	13
45-64	12	0.7	133	0.7	96	615	36.1	6,130	0.5	35	955	56.0	9,455	0.4	21
65-74	11	4.4	118	1.4	97	45	17.9	492	0.8	41	113	45.0	1,243	0.3	24
75-84	12	5.6	128	1.3	87	33	15.4	350	1.1	43	87	40.7	959	0.3	9
85 and older	3	5.8	36	1.0	102	8	15.4	80	1.2	38	10	19.2	105	0.4	8
<b>Male</b>															
All Males	127	0.2	1,342	0.9	3,203	2,960	5.5	30,500	0.8	40	7,698	14.3	75,931	0.3	18
<b>Male, Disabled</b>															
All Ages	82	2.0	900	0.8	1,671	1,253	30.1	13,800	1.0	51	1,871	45.0	20,157	0.5	45
5 and younger	0	0.0	0	0.0	0	1	0.4	10	0.3	20	25	9.9	284	0.1	2
6-14	2	0.3	15	0.6	12,358	105	18.0	1,213	0.7	37	68	11.7	777	0.1	2
15-20	1	0.2	12	1.9	103,899	107	23.3	1,186	0.9	49	90	19.6	996	0.2	6
21-44	4	0.4	43	0.2	24	403	35.4	4,412	1.1	56	500	44.0	5,367	0.4	28
45-64	74	4.4	826	0.9	85	625	37.4	6,855	1.1	50	1,158	69.2	12,438	0.6	60
65-74	1	1.9	4	0.5	75	12	23.1	124	1.5	46	27	51.9	265	0.3	7
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	300.0	30	0.1	1
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Beneficiaries

TABLE ND.7B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	MISC. HEMATOLOGICAL					ANTIDEPRESSANTS					ANALGESICS - Narcotic				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>Male, Other Eligibles</b>															
All Ages	45	0.1	442	0.9	6,321	1,707	3.4	16,700	0.6	31	5,827	11.7	55,774	0.2	8
5 and younger	2	0.0	23	0.5	241	13	0.1	151	0.3	8	607	3.8	6,189	0.1	1
6-14	3	0.0	36	0.4	15,098	442	2.4	4,789	0.6	28	1,214	6.5	12,806	0.1	2
15-20	5	0.1	55	0.5	40,288	626	7.0	6,196	0.7	36	1,629	18.2	15,601	0.1	3
21-44	8	0.2	76	0.6	87	448	10.2	3,856	0.3	24	1,767	40.2	15,221	0.3	16
45-64	11	0.9	88	0.6	83	139	11.0	1,292	0.4	35	511	40.3	4,875	0.4	20
65-74	8	5.1	82	1.8	98	21	13.4	217	1.0	25	62	39.5	676	0.3	22
75-84	6	6.2	58	1.0	80	10	10.3	110	0.6	48	31	32.0	336	0.3	15
85 and older	2	7.4	24	2.2	100	8	29.6	89	2.0	49	6	22.2	70	0.2	26
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7B includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	ULCER DRUGS					ANTIASTHMATIC					STIMULANTS/ANTI-OBESITY/ANOREXIANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>All</b>	<b>6,869</b>	<b>5.7</b>	<b>69,368</b>	<b>0.5</b>	<b>\$50</b>	<b>18,207</b>	<b>15.2</b>	<b>185,221</b>	<b>0.3</b>	<b>\$19</b>	<b>3,912</b>	<b>3.3</b>	<b>40,979</b>	<b>0.6</b>	<b>\$65</b>
<b>Female</b>															
All Females	4,667	7.1	47,228	0.5	49	10,161	15.4	102,717	0.3	19	1,228	1.9	12,969	0.6	69
<b>Female, Disabled</b>															
All Ages	1,580	38.0	17,852	0.8	73	1,937	46.6	21,875	0.4	34	197	4.7	2,213	0.7	88
5 and younger	39	20.3	413	0.3	27	83	43.2	889	0.3	20	3	1.6	30	0.5	30
6-14	24	8.6	288	0.4	55	67	24.0	784	0.3	19	38	13.6	435	0.7	80
15-20	34	12.5	370	0.4	50	58	21.4	632	0.4	48	30	11.1	322	0.7	75
21-44	397	30.4	4,560	0.8	69	498	38.1	5,750	0.3	26	60	4.6	685	0.6	80
45-64	1,044	51.4	11,738	0.8	78	1,189	58.6	13,397	0.5	38	64	3.2	735	0.7	108
65-74	39	52.0	447	0.8	78	42	56.0	423	0.4	24	2	2.7	6	0.8	28
75-84	3	60.0	36	0.4	50	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Female, Other Eligibles</b>															
All Ages	3,087	5.0	29,376	0.3	34	8,224	13.3	80,842	0.2	15	1,031	1.7	10,756	0.5	65
5 and younger	244	1.6	2,283	0.2	18	2,054	13.6	20,479	0.2	9	23	0.2	230	0.4	35
6-14	256	1.4	2,667	0.2	23	2,041	11.5	21,172	0.2	15	541	3.1	5,837	0.6	59
15-20	491	4.6	4,633	0.2	24	1,324	12.5	12,734	0.2	14	236	2.2	2,401	0.5	61
21-44	1,549	9.6	14,180	0.3	33	2,222	13.8	20,491	0.2	16	187	1.2	1,836	0.5	85
45-64	373	21.9	3,638	0.4	47	418	24.5	4,085	0.3	28	44	2.6	452	0.6	94
65-74	94	37.5	1,074	0.7	71	75	29.9	836	0.4	37	0	0.0	0	0.0	0
75-84	73	34.1	823	0.7	74	79	36.9	913	0.4	41	0	0.0	0	0.0	0
85 and older	7	13.5	78	0.9	106	11	21.2	132	0.5	29	0	0.0	0	0.0	0
<b>Male</b>															
All Males	2,202	4.1	22,140	0.5	52	8,046	15.0	82,504	0.2	18	2,684	5.0	28,010	0.6	64
<b>Male, Disabled</b>															
All Ages	904	21.7	9,732	0.8	78	1,006	24.2	11,129	0.4	38	359	8.6	4,005	0.7	77
5 and younger	37	14.6	388	0.4	41	95	37.5	1,013	0.3	25	12	4.7	137	0.7	54
6-14	42	7.2	480	0.7	76	122	20.9	1,404	0.3	24	197	33.8	2,275	0.7	75
15-20	44	9.6	496	0.6	81	90	19.6	1,030	0.3	46	88	19.1	980	0.7	77
21-44	215	18.9	2,312	0.8	73	185	16.3	1,996	0.3	29	35	3.1	355	0.6	83
45-64	545	32.6	5,839	0.9	82	499	29.8	5,542	0.5	44	26	1.6	246	0.7	107
65-74	21	40.4	217	1.3	97	14	26.9	134	0.5	56	1	1.9	12	0.3	41
75-84	0	0.0	0	0.0	0	1	100.0	10	1.2	196	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Nondual Beneficiaries

TABLE ND.7C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY,  
 BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	ULCER DRUGS					ANTIASTHMATIC					STIMULANTS/ANTI-OBESITY/ANOREXIANTS				
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Rx per Benefit Month	Mean Rx \$ per Benefit Month
<b>Male, Other Eligibles</b>															
All Ages	1,298	2.6	12,408	0.3	32	7,040	14.2	71,375	0.2	15	2,325	4.7	24,005	0.6	62
5 and younger	308	1.9	2,844	0.2	17	2,975	18.5	30,056	0.2	11	91	0.6	973	0.5	42
6-14	251	1.3	2,628	0.2	23	2,601	14.0	27,148	0.2	18	1,665	8.9	17,434	0.6	62
15-20	186	2.1	1,793	0.3	25	830	9.3	8,219	0.2	16	515	5.8	5,155	0.6	65
21-44	321	7.3	2,839	0.3	42	360	8.2	3,179	0.2	14	49	1.1	420	0.4	58
45-64	148	11.7	1,372	0.4	55	143	11.3	1,366	0.3	24	5	0.4	23	0.3	65
65-74	52	33.1	567	0.5	52	55	35.0	612	0.4	37	0	0.0	0	0.0	0
75-84	24	24.7	276	0.6	62	50	51.5	557	0.5	53	0	0.0	0	0.0	0
85 and older	8	29.6	89	1.1	59	26	96.3	238	0.5	33	0	0.0	0	0.0	0
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7C includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	PASSIVE IMMUNIZING AGENTS					DERMATOLOGICAL					Number of Beneficiaries	Number of Benefit Months
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month		
<b>All</b>	<b>393</b>	<b>0.3</b>	<b>3,473</b>	<b>0.5</b>	<b>\$719</b>	<b>18,634</b>	<b>15.6</b>	<b>188,417</b>	<b>0.2</b>	<b>\$9</b>	<b>119,692</b>	<b>1,019,186</b>
<b>Female</b>												
All Females	187	0.3	1,670	0.5	661	11,447	17.4	115,352	0.2	9	65,896	551,612
<b>Female, Disabled</b>												
All Ages	36	0.9	358	0.5	641	1,669	40.1	19,201	0.2	13	4,159	43,568
5 and younger	35	18.2	346	0.5	662	64	33.3	705	0.1	5	192	1,832
6-14	0	0.0	0	0.0	0	91	32.6	1,070	0.1	7	279	3,086
15-20	0	0.0	0	0.0	0	122	45.0	1,358	0.1	9	271	2,859
21-44	1	0.1	12	0.1	9	498	38.1	5,795	0.2	12	1,307	13,929
45-64	0	0.0	0	0.0	0	865	42.6	9,935	0.2	15	2,030	21,062
65-74	0	0.0	0	0.0	0	29	38.7	338	0.2	12	75	751
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	5	49
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Female, Other Eligibles</b>												
All Ages	151	0.2	1,312	0.5	666	9,778	15.8	96,151	0.1	8	61,737	508,044
5 and younger	144	1.0	1,259	0.5	694	3,351	22.2	32,946	0.1	5	15,091	127,986
6-14	0	0.0	0	0.0	0	2,251	12.7	23,348	0.1	8	17,736	163,696
15-20	2	0.0	17	0.1	15	1,655	15.6	16,248	0.2	10	10,610	86,505
21-44	5	0.0	36	0.1	17	2,112	13.1	19,273	0.2	11	16,078	110,207
45-64	0	0.0	0	0.0	0	305	17.9	3,219	0.2	11	1,705	14,268
65-74	0	0.0	0	0.0	0	44	17.5	468	0.2	7	251	2,602
75-84	0	0.0	0	0.0	0	53	24.8	586	0.3	9	214	2,320
85 and older	0	0.0	0	0.0	0	7	13.5	63	0.3	8	52	460
<b>Male</b>												
All Males	206	0.4	1,803	0.5	774	7,187	13.4	73,065	0.2	9	53,793	467,550
<b>Male, Disabled</b>												
All Ages	34	0.8	326	0.5	746	1,009	24.3	11,264	0.2	12	4,159	41,742
5 and younger	34	13.4	326	0.5	746	80	31.6	873	0.1	5	253	2,402
6-14	0	0.0	0	0.0	0	121	20.8	1,371	0.2	10	583	6,395
15-20	0	0.0	0	0.0	0	140	30.4	1,583	0.2	17	460	4,757
21-44	0	0.0	0	0.0	0	213	18.7	2,393	0.2	14	1,137	11,488
45-64	0	0.0	0	0.0	0	441	26.4	4,882	0.2	11	1,673	16,189
65-74	0	0.0	0	0.0	0	13	25.0	152	0.1	4	52	501
75-84	0	0.0	0	0.0	0	1	100.0	10	0.1	6	1	10
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Nondual Beneficiaries



TABLE ND.7D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a</sup>, b, c  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	PASSIVE IMMUNIZING AGENTS						DERMATOLOGICAL					
	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Users	Users as % of All Benes	Number of Benefit Months Among Users	Mean Number of Rx per Benefit Month	Mean Rx \$ per Benefit Month	Number of Beneficiaries	Number of Benefit Months
<b>Male, Other Eligibles</b>												
All Ages	172	0.3	1,477	0.5	780	6,178	12.4	61,801	0.1	8	49,634	425,808
5 and younger	172	1.1	1,477	0.5	780	3,180	19.7	31,215	0.1	6	16,103	135,453
6-14	0	0.0	0	0.0	0	1,585	8.5	16,612	0.1	8	18,641	171,673
15-20	0	0.0	0	0.0	0	1,034	11.6	10,426	0.2	15	8,948	74,906
21-44	0	0.0	0	0.0	0	231	5.3	2,050	0.2	12	4,393	30,910
45-64	0	0.0	0	0.0	0	107	8.4	1,047	0.2	12	1,268	10,163
65-74	0	0.0	0	0.0	0	25	15.9	263	0.2	9	157	1,475
75-84	0	0.0	0	0.0	0	11	11.3	128	0.2	7	97	975
85 and older	0	0.0	0	0.0	0	5	18.5	60	0.2	2	27	253
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	24

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.7D includes the beneficiaries represented by Cell K of Table 1. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. The top 10 drug groups were determined based on total Medicaid reimbursement in the state for 2005. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispn.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; Rx = prescription (s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.8  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BENEFICIARY CHARACTERISTIC<sup>a, b</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	Rx \$ per Benefit Month	Number of Rx per Benefit Month	Number of All-Year Nursing Facility Residents	Benefit Months Among All- Year Nursing Facility Residents
<b>All</b>	<b>\$752</b>	<b>8.9</b>	<b>71</b>	<b>665</b>
<b>Age</b>				
0-64	835	9.8	56	521
65-74	353	4.1	4	47
75-84	641	7.1	7	65
85 and older	220	5.1	4	32
Unknown	0	0.0	0	0
<b>Gender</b>				
Female	784	9.2	43	425
Male	696	8.5	28	240
Unknown	0	0.0	0	0
<b>Race</b>				
White	863	11.5	28	254
African American	145	3.3	4	37
Other/unknown	737	7.7	39	374
<b>Basis of Eligibility<sup>c</sup></b>				
Aged	591	6.7	16	156
Disabled	802	9.6	55	509
Adults	0	0.0	0	0
Children	0	0.0	0	0
Unknown	0	0.0	0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.8 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their 2005 Medicaid enrollment. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

b. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.9  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY BRAND STATUS AND THERAPEUTIC CATEGORY<sup>a, b, c, d, e</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

	Number of Rx per Benefit Month Among Users				\$ per Benefit Month Among Users				\$ per Rx				Users				
Therapeutic Category	Total	Patented Brand- Name	Off- Patent Brand- Name	Generic	Total	Patented Brand- Name	Off- Patent Brand- Name	Generic	Total	Patented Brand- Name	Off- Patent Brand- Name	Generic	Total Number of Rx	Total Rx \$	Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months
Anti-infective Agents	0.5	0.1	0.1	0.3	\$79	\$60	\$7	\$12	\$171	\$406	\$133	\$48	215	\$36,837	43	60.6	464
Biologicals	0.1	0.0	0.0	0.1	4	0	0	4	38	0	0	38	1	38	1	1.4	9
Antineoplastic Agents	0.7	0.0	0.0	0.7	57	0	0	57	83	0	0	83	20	1,657	3	4.2	29
Endocrine/Metabolic Drugs	1.7	0.7	0.3	0.7	94	51	31	12	57	71	111	18	470	26,663	31	43.7	284
Cardiovascular Agents	1.9	0.5	0.1	1.3	83	60	1	23	44	117	14	17	639	28,098	38	53.5	337
Respiratory Agents	1.0	0.6	0.0	0.3	84	76	0	8	87	123	0	22	215	18,735	22	31.0	224
Gastrointestinal Agents	1.5	0.7	0.1	0.7	96	72	5	19	63	103	41	28	801	50,677	56	78.9	528
Genitourinary Agents	1.0	0.4	0.4	0.2	54	37	10	7	56	89	29	36	125	6,976	12	16.9	129
CNS Drugs	2.5	1.2	0.0	1.2	242	198	5	40	98	166	120	32	1,305	128,029	54	76.1	529
Stimulants/Anti-obesity/Anorexia	1.0	0.1	0.0	1.0	29	8	0	21	28	147	0	22	57	1,615	7	9.9	55
Miscellaneous Psychological/ Neurological Agents	1.3	1.3	0.0	0.0	735	735	0	0	555	555	0	0	41	22,771	3	4.2	31
Analgesics and Anesthetics	1.3	0.1	0.2	1.0	164	74	30	60	122	508	145	60	515	62,763	41	57.7	383
Neuromuscular Agents	1.8	0.2	0.0	1.5	138	33	9	96	79	182	189	63	877	69,263	48	67.6	501
Nutritional Products	1.1	0.0	0.0	1.0	20	1	1	18	18	49	37	17	210	3,859	21	29.6	193
Hematological Agents	1.2	0.3	0.3	0.6	127	106	9	11	107	397	27	19	163	17,457	18	25.4	138
Topical Products	0.5	0.1	0.0	0.4	22	6	1	15	48	98	39	40	191	9,130	39	54.9	406
Miscellaneous Products	1.2	0.3	0.0	0.9	355	129	0	226	293	410	0	252	46	13,492	5	7.0	38
Unknown Therapeutic Category	0.6	0.0	0.0	0.0	34	0	0	0	55	0	0	0	38	2,072	7	9.9	61
<b>TOTAL NO. OF RX AND RX \$</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>	<b>5,929</b>	<b>500,132</b>	<b>n.a.</b>	<b>n.a.</b>	<b>n.a.</b>

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.9 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given therapeutic category during 2005. A beneficiary who used drugs from two or more categories was counted as a user for each category. Therefore, the sum of users across categories may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. For information about these therapeutic categories, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

e. Brand-name drugs, sometimes called "innovator single-source drugs," are drugs whose patents have not yet expired. Off-patent brand-name drugs, sometimes called "innovator multiple-source drugs," are brand-name drugs whose patents have expired. Generic drugs, sometimes called "non-innovator multiple-source drugs," are off-patent drugs manufactured and sold by companies other than the original patent holder. For information about this classification method, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

In Alaska, 2.0 percent of drug claims have missing values for brand status. Thus, the sum of the three groups in this table may be smaller than all prescriptions combined.

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; CNS = Central Nervous System; MAX = Medicaid Analytic Extract; n.a. = not applicable; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.10  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT FOR TOP 10 DRUG GROUPS AMONG ALL-YEAR NURSING FACILITY RESIDENTS,  
 BY TOP-10 DRUG GROUP<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Top 10 Drug Groups in Nursing Facilities	Total Medicaid Rx \$	Users			Among Users		
		Number of Users	As a Percentage of All-Year Nursing Facility Residents	Number of Benefit Months	Number of Rx per Benefit Month	\$ per Rx	Rx \$ per Benefit Month
ANTIPSYCHOTICS	\$70,970	30	42.3	275	1.2	\$214	\$258
ANTIDEPRESSANTS	47,977	55	77.5	567	1.2	73	85
ANTICONVULSANT	46,172	38	53.5	431	1.3	79	107
ULCER DRUGS	35,113	40	56.3	378	1.1	81	93
ANALGESICS - Narcotic	33,444	49	69.0	464	0.9	83	72
ANALGESICS - ANTI-INFLAMMATORY	25,739	8	11.3	87	0.6	468	296
MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL	22,771	4	5.6	38	1.1	555	599
MUSCULOSKELETAL THERAPY AGENTS	21,768	23	32.4	255	1.0	82	85
ANTIVIRAL	18,911	4	5.6	48	0.8	511	394
ANTIASTHMATIC	15,746	24	33.8	248	0.6	111	63
Total	338,611	275		2,791	n.a.	n.a.	n.a.

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10 includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

TABLE ND.10A  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR TOP 10 DRUG GROUPS COMBINED AND FIRST  
 AND SECOND TOP DRUG GROUPS SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	All Top 10 Drug Groups			ANTIPSYCHOTICS				ANTIDEPRESSANTS				
	Number of Rx	Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
<b>All</b>	<b>2,945</b>	<b>\$338,611</b>	<b>30</b>	<b>42.3</b>	<b>275</b>	<b>1.2</b>	<b>\$258</b>	<b>55</b>	<b>77.5</b>	<b>567</b>	<b>1.2</b>	<b>\$85</b>
<b>Female</b>												
All Females	1,880	223,629	17	39.5	138	1.2	251	37	86.0	374	1.3	98
<b>Female, Disabled</b>												
All Ages	1,597	191,214	11	35.5	92	1.0	248	32	103.2	335	1.3	95
64 or younger	1,597	191,214	11	35.5	92	1.0	248	32	103.2	335	1.3	95
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Female, Other Eligibles</b>												
All Ages	283	32,415	6	50.0	46	1.4	256	5	41.7	39	1.1	117
64 or younger	40	2,306	0	0.0	0	0.0	0	1	100.0	12	0.9	30
65-74	120	13,328	1	25.0	12	1.0	229	1	25.0	11	1.0	265
75-84	108	15,029	5	125.0	34	1.5	266	3	75.0	16	1.3	81
85 and older	15	1,752	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Male</b>												
All Males	1,065	114,982	13	46.4	137	1.3	266	18	64.3	193	0.9	59
<b>Male, Disabled</b>												
All Ages	874	96,760	11	45.8	113	1.3	276	15	62.5	157	1.0	57
64 or younger	874	96,760	11	45.8	113	1.3	276	15	62.5	157	1.0	57
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Male, Other Eligibles</b>												
All Ages	191	18,222	2	50.0	24	1.1	214	3	75.0	36	0.8	72
64 or younger	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	161	16,519	2	66.7	24	1.1	214	3	100.0	36	0.8	72
85 and older	30	1,703	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Unknown</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0.0</b>	<b>0</b>	<b>0.0</b>	<b>0</b>	<b>0</b>	<b>0.0</b>	<b>0</b>	<b>0.0</b>	<b>0</b>

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10A includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10B  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR THIRD TO FIFTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	ANTICONVULSANT					ULCER DRUGS					ANALGESICS - Narcotic				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
<b>All</b>	<b>38</b>	<b>53.5</b>	<b>431</b>	<b>1.3</b>	<b>\$107</b>	<b>40</b>	<b>56.3</b>	<b>378</b>	<b>1.1</b>	<b>\$93</b>	<b>49</b>	<b>69.0</b>	<b>464</b>	<b>0.9</b>	<b>\$72</b>
<b>Female</b>															
All Females	24	55.8	275	1.4	123	24	55.8	249	1.1	100	28	65.1	269	1.0	106
<b>Female, Disabled</b>															
All Ages	20	64.5	231	1.5	139	16	51.6	158	1.2	103	23	74.2	230	1.1	99
64 or younger	20	64.5	231	1.5	139	16	51.6	158	1.2	103	23	74.2	230	1.1	99
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Female, Other Eligibles</b>															
All Ages	4	33.3	44	1.1	37	8	66.7	91	1.0	95	5	41.7	39	0.9	147
64 or younger	1	100.0	12	1.3	61	1	100.0	12	1.1	101	0	0.0	0	0.0	0
65-74	2	50.0	24	1.2	33	4	100.0	47	0.9	68	2	50.0	24	1.1	154
75-84	1	25.0	8	0.6	16	2	50.0	20	1.1	126	2	50.0	12	0.8	170
85 and older	0	0.0	0	0.0	0	1	33.3	12	1.1	144	1	33.3	3	0.7	8
<b>Male</b>															
All Males	14	50.0	156	1.2	80	16	57.1	129	1.2	80	21	75.0	195	0.6	25
<b>Male, Disabled</b>															
All Ages	12	50.0	132	1.2	88	14	58.3	105	1.3	87	16	66.7	135	0.8	34
64 or younger	12	50.0	132	1.2	88	14	58.3	105	1.3	87	16	66.7	135	0.8	34
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Male, Other Eligibles</b>															
All Ages	2	50.0	24	1.1	35	2	50.0	24	0.8	49	5	125.0	60	0.3	4
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	2	66.7	24	1.1	35	1	33.3	12	1.0	89	4	133.3	48	0.4	5
85 and older	0	0.0	0	0.0	0	1	100.0	12	0.6	9	1	100.0	12	0.1	1
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10B includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10C  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR SIXTH TO EIGHTH TOP DRUG GROUPS SEPARATELY  
 AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	ANALGESICS - ANTI-INFLAMMATORY					MISC PSYCHOTHERAPEUTIC AND NEUROLOGICAL					MUSCULOSKELETAL THERAPY AGENTS				
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$
<b>All</b>	<b>8</b>	<b>11.3</b>	<b>87</b>	<b>0.6</b>	<b>\$296</b>	<b>4</b>	<b>5.6</b>	<b>38</b>	<b>1.1</b>	<b>\$599</b>	<b>23</b>	<b>32.4</b>	<b>255</b>	<b>1.0</b>	<b>\$85</b>
<b>Female</b>															
All Females	7	16.3	75	0.7	343	2	4.7	24	1.0	858	15	34.9	170	1.1	95
<b>Female, Disabled</b>															
All Ages	7	22.6	75	0.7	343	2	6.5	24	1.0	858	15	48.4	170	1.1	95
64 or younger	7	22.6	75	0.7	343	2	6.5	24	1.0	858	15	48.4	170	1.1	95
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Female, Other Eligibles</b>															
All Ages	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Male</b>															
All Males	1	3.6	12	0.2	2	2	7.1	14	1.1	155	8	28.6	85	1.0	66
<b>Male, Disabled</b>															
All Ages	1	4.2	12	0.2	2	2	8.3	14	1.1	155	7	29.2	73	1.2	76
64 or younger	1	4.2	12	0.2	2	2	8.3	14	1.1	155	7	29.2	73	1.2	76
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
<b>Male, Other Eligibles</b>															
All Ages	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	25.0	12	0.1	1
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	100.0	12	0.1	1
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0.0	0	0.0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10C includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispan.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.10D  
 MEDICAID PHARMACY BENEFIT USE AND REIMBURSEMENT PER BENEFIT MONTH FOR NINTH AND TENTH TOP DRUG GROUPS  
 SEPARATELY AMONG ALL-YEAR NURSING FACILITY RESIDENTS, BY SEX, BASIS OF ELIGIBILITY, AND AGE<sup>a, b, c, d</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	ANTIVIRAL					ANTIASTHMATIC					All-Year Nursing Facility Residents	Benefit Months Among All-Year Nursing Facility Residents
	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$	Number of Users	Users as % of All-Year Nursing Facility Residents	Number of Benefit Months Among Users	Mean Number of Rx	Mean Rx \$		
<b>All</b>	<b>4</b>	<b>5.6</b>	<b>48</b>	<b>0.8</b>	<b>\$394</b>	<b>24</b>	<b>33.8</b>	<b>248</b>	<b>0.6</b>	<b>\$64</b>	<b>71</b>	<b>665</b>
<b>Female</b>												
All Females	1	2.3	12	0.1	2	8	18.6	74	0.4	38	43	425
<b>Female, Disabled</b>												
All Ages	1	3.2	12	0.1	2	8	25.8	74	0.4	38	31	317
64 or younger	1	3.2	12	0.1	2	8	25.8	74	0.4	38	31	317
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Female, Other Eligibles</b>												
All Ages	0	0.0	0	0.0	0	0	0.0	0	0.0	0	12	108
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	1	12
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	47
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	4	29
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	3	20
<b>Male</b>												
All Males	3	10.7	36	1.0	525	16	57.1	174	0.6	75	28	240
<b>Male, Disabled</b>												
All Ages	3	12.5	36	1.0	525	8	33.3	78	0.5	61	24	192
64 or younger	3	12.5	36	1.0	525	8	33.3	78	0.5	61	24	192
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
85 and older	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
<b>Male, Other Eligibles</b>												
All Ages	0	0.0	0	0.0	0	8	200.0	96	0.7	86	4	48
64 or younger	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
65-74	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0
75-84	0	0.0	0	0.0	0	4	133.3	48	1.0	139	3	36
85 and older	0	0.0	0	0.0	0	4	400.0	48	0.4	33	1	12
<b>Unknown</b>	0	0.0	0	0.0	0	0	0.0	0	0.0	0	0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.10D includes the beneficiaries represented by Cell L of Table 1, those who resided in nursing facilities throughout their Medicaid enrollment in 2005. A total of 97 beneficiaries who were in nursing facilities for part of their enrollment and their 911 benefit months were excluded from the analysis.

b. A user is a beneficiary who had at least one prescription filled in a given drug group during 2005. A beneficiary who used drugs from two or more drug groups was counted as a user for each group. Therefore, the sum of users across drug groups may exceed the total number of individual users. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits.

c. Medicaid reimbursement amounts presented in this table do not reflect federally required rebates from drug manufacturers to the state.

d. The top 10 drug groups were determined based on total 2005 Medicaid reimbursement for all-year nursing facility residents in this state. For information about these drug groups, see Wolters Kluwer Health, <http://www.medispain.com/marketing/ContentPage.aspx?contentId=09e0f1ed-80a9-4a87-8bc9-ad778d7b6615> (October 26, 2007).

Bene Mo(s) = benefit month(s); BOE = basis of eligibility; CMS = Centers for Medicare & Medicaid Services; MAX = Medicaid Analytic Extract; NF = nursing facility; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.



TABLE ND.11  
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
AMONG NONDUALS, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
ALASKA, 2005

Beneficiary Characteristics	Number of Beneficiaries with at Least One Part D Excluded Rx	Percentage of Beneficiaries with at Least One Part D Excluded Rx	Number of Part D Excluded Rx per Beneficiary	Total Number Part D Excluded Rx	Part D Excluded Rx \$ per Beneficiary	Total Part D Excluded Rx \$	\$ per Part D Excluded Rx	Part D Excluded Rx \$ as a Percentage of All Nondual Rx \$	Total Number of Beneficiaries
<b>All</b>	<b>9,679</b>	<b>8.1</b>	<b>0.4</b>	<b>43,323</b>	<b>\$7</b>	<b>\$896,043</b>	<b>\$21</b>	<b>1.3</b>	<b>119,692</b>
<b>Age</b>									
5 and younger	1,450	4.6	0.1	2,951	2	74,317	25	1.3	31,642
6-14	802	2.2	0.1	1,979	2	72,824	37	0.7	37,239
15-20	1,307	6.4	0.2	3,270	3	65,599	20	0.6	20,289
21-44	4,027	17.6	0.7	17,015	15	333,413	20	1.7	22,915
45-64	1,889	28.3	2.4	16,237	48	322,188	20	1.6	6,676
65-74	109	20.4	2.3	1,237	35	18,797	15	1.6	535
75-84	74	23.3	1.6	499	21	6,727	13	1.0	317
85 and older	21	26.6	1.7	135	28	2,178	16	1.3	79
Unknown	0	0.0	0.0	0	0	0	0	0.0	0
<b>Basis of Eligibility<sup>c</sup></b>									
Aged	173	21.4	1.9	1,547	27	21,765	14	1.3	808
Disabled	2,529	30.4	2.8	23,002	67	553,467	24	1.6	8,318
Adults	4,141	14.7	0.5	13,134	8	211,488	16	1.7	28,091
Children	2,804	3.4	0.1	5,527	1	106,925	19	0.6	82,317
Unknown	32	20.3	0.7	113	15	2,398	21	0.6	158
<b>Gender</b>									
Female	6,918	10.5	0.5	30,326	9	591,775	20	1.6	65,896
Male	2,761	5.1	0.2	12,997	6	304,268	23	1.0	53,793
Unknown	0	0.0	0.0	0	0	0	0	0.0	3
<b>Race</b>									
White	4,430	9.2	0.5	24,384	11	544,194	22	1.5	48,376
African American	386	6.0	0.3	1,698	5	31,589	19	0.7	6,483
Other/unknown	4,863	7.5	0.3	17,241	5	320,260	19	1.2	64,833
<b>Use of Nursing Facilities<sup>d</sup></b>									
Entire year	43	60.6	7.8	552	141	10,017	18	2.0	71
Part year	61	62.9	5.3	516	117	11,386	22	1.9	97
None	9,575	8.0	0.4	42,255	7	874,640	21	1.3	119,524
<b>Maintenance Assistance Status</b>									
Cash	5,579	13.5	0.8	33,774	17	697,032	21	1.5	41,454
Medically needy	0	0.0	0.0	0	0	0	0	0.0	0
Poverty related	3,208	4.9	0.1	6,306	2	98,676	16	0.8	65,734
Other/unknown	892	7.1	0.3	3,243	8	100,335	31	1.1	12,504

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.11 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

TABLE ND.12  
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D  
AMONG NONDUALS PER BENEFIT MONTH, BY BENEFICIARY CHARACTERISTIC<sup>a,b</sup>  
ALASKA, 2005

Beneficiary Characteristics	Number Rx per Benefit Month	Rx \$ per Benefit Month	\$ per Rx	Barbiturate \$ per Benefit Month	Benzodiazepine \$ per Benefit Month	Number of Benefit Months
<b>All</b>	<b>0.0</b>	<b>\$1</b>	<b>\$21</b>	<b>\$0</b>	<b>\$1</b>	<b>1,019,186</b>
<b>Age</b>						
5 and younger	0.0	0	25	0	0	267,697
6-14	0.0	0	37	0	0	344,850
15-20	0.0	0	20	0	0	169,027
21-44	0.1	2	20	0	1	166,534
45-64	0.3	5	20	0	3	61,682
65-74	0.2	4	15	0	1	5,329
75-84	0.1	2	13	0	0	3,354
85 and older	0.2	3	16	0	0	713
Unknown	0.0	0	0	0	0	0
<b>Basis of Eligibility<sup>c</sup></b>						
Aged	0.2	3	14	0	1	8,184
Disabled	0.3	6	24	0	4	85,310
Adults	0.1	1	16	0	1	199,032
Children	0.0	0	19	0	0	725,664
Unknown	0.1	2	21	0	1	996
<b>Gender</b>						
Female	0.1	1	20	0	1	551,612
Male	0.0	1	23	0	0	467,550
Unknown	0.0	0	0	0	0	24
<b>Race</b>						
White	0.1	1	22	0	1	404,430
African American	0.0	1	19	0	0	55,935
Other/unknown	0.0	1	19	0	0	558,821
<b>Use of Nursing Facilities<sup>d</sup></b>						
Entire year	0.8	15	18	0	8	665
Part year	0.6	12	22	0	6	911
None	0.0	1	21	0	1	1,017,610
<b>Maintenance Assistance Status</b>						
Cash	0.1	2	21	0	1	367,483
Medically needy	0.0	0	0	0	0	0
Poverty related	0.0	0	16	0	0	537,346
Other/unknown	0.0	1	31	0	0	114,357

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.12 includes the beneficiaries represented by Cell K of Table 1. Benefit months are months during which beneficiaries had fee-for-service pharmacy benefits. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005.

b. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

c. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services.

d. Please refer to footnote f on Table 1 for methodology used to determine use of nursing facilities.

TABLE ND.13  
USE AND REIMBURSEMENT FOR DRUGS EXCLUDED BY STATUTE FROM MEDICARE PART D FOR SELECTED DRUG CATEGORIES AMONG NONDUALS<sup>a,b,c</sup>  
ALASKA, 2005

Drug Category	Number of Users	Rx \$ per User	Total Rx \$	Rx \$ as a Percentage of All Part D Excluded Rx \$	Total Number Rx.	\$ per Rx	Number Rx as a Percentage of All Part D Excluded Rx
<b>All</b>	<b>11,039</b>	<b>\$81</b>	<b>\$896,043</b>	<b>100.0</b>	<b>43,323</b>	<b>\$21</b>	<b>100.0</b>
Anorexia or weight loss/gain	0	0	0	0.0	0	0	0.0
Fertility drugs	0	0	0	0.0	0	0	0.0
Drugs for cosmetic purposes	39	35	1,371	0.2	66	21	0.2
Cough and cold medications	619	113	69,833	7.8	1,205	58	2.8
Vitamins and minerals	1,701	93	158,645	17.7	8,455	19	19.5
Non-prescription drugs	3,418	26	89,287	10.0	9,008	10	20.8
Barbiturates	148	81	12,032	1.3	973	12	2.2
Benzodiazepines	4,237	124	523,561	58.4	21,619	24	49.9
Other Part D Excl Rx Drugs	877	47	41,314	4.6	1,997	21	4.6

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table ND.13 includes the beneficiaries represented by Cell K of Table 1. Beneficiaries include all nondual Medicaid beneficiaries who had Medicaid pharmacy benefits during at least one month in 2005. A user is a beneficiary who had at least one prescription filled for a Part D excluded drug in 2005. A beneficiary who used drugs from two or more Part D excluded categories was counted as a user for each category. Therefore, the sum of users across drug categories may exceed the total number of individual users as noted on Table ND11.

b. Includes OTC drugs as well as prescription drugs.

c. The statute establishing the Medicare Part D prescription program that started in 2006 excludes several types of drugs from coverage. State Medicaid programs have been allowed to exclude these drugs since 1990, but many states have chosen to cover them, and if states cover them for any Medicaid beneficiaries they must also cover them for dual eligibles, who as of 2006 receive the remainder of their prescription drug coverage through Part D. Excluded drugs include benzodiazepines; barbiturates; nonprescription (OTC) medications; prescription vitamins and minerals (not including prenatal vitamins and fluoride preparations); and drugs used for anorexia, weight loss, or weight gain. Other excluded drugs include those that promote fertility; those used for cosmetic purposes or hair growth, for symptomatic relief of coughs and colds; or drugs for which the manufacturer requires that associated tests or monitoring services be purchased exclusively from the manufacturer.

Bene(s) = beneficiary (or beneficiaries); CMS = Centers for Medicare & Medicaid Services; Excl = excluded; MAX = Medicaid Analytic Extract; OTC = over-the-counter; Rx = prescription(s) or pharmacy benefit; \$ = Medicaid reimbursement.

Nondual Beneficiaries

APPENDIX TABLE A.1  
CHARACTERISTICS OF MEDICAID BENEFICIARIES WITH AT LEAST ONE MONTH OF PHARMACY BENEFIT COVERAGE, BY BASIS OF ELIGIBILITY<sup>a, b</sup>  
NONDUAL BENEFICIARIES, ALASKA, 2005

Beneficiary Characteristics	Number of Beneficiaries						Number of Benefit Months					
	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown	All	Aged	Blind/ Disabled	Adults	Children	Other/ Unknown
<b>All</b>	<b>119,692</b>	<b>808</b>	<b>8,318</b>	<b>28,091</b>	<b>82,317</b>	<b>158</b>	<b>1,019,186</b>	<b>8,184</b>	<b>85,310</b>	<b>199,032</b>	<b>725,664</b>	<b>996</b>
<b>Age</b>												
5 and younger	31,642	0	445	0	31,197	0	267,697	0	4,234	0	263,463	0
6-14	37,239	0	862	4	36,373	0	344,850	0	9,481	29	335,340	0
15-20	20,289	0	731	5,039	14,514	5	169,027	0	7,616	35,608	125,792	11
21-44	22,915	0	2,444	20,142	233	96	166,534	0	25,417	139,547	1,069	501
45-64	6,676	15	3,703	2,902	0	56	61,682	143	37,251	23,808	0	480
65-74	535	403	127	4	0	1	5,329	4,033	1,252	40	0	4
75-84	317	311	6	0	0	0	3,354	3,295	59	0	0	0
85 and older	79	79	0	0	0	0	713	713	0	0	0	0
Unknown	0	0	0	0	0	0	0	0	0	0	0	0
<b>Gender</b>												
Female	65,896	523	4,159	20,962	40,094	158	551,612	5,457	43,568	146,772	354,819	996
Male	53,793	285	4,159	7,129	42,220	0	467,550	2,727	41,742	52,260	370,821	0
Unknown	3	0	0	0	3	0	24	0	0	0	24	0
<b>Race</b>												
White	48,376	157	4,407	12,204	31,481	127	404,430	1,419	44,823	83,951	273,452	785
African American	6,483	17	506	1,393	4,563	4	55,935	151	5,072	9,919	40,764	29
Other/unknown	64,833	634	3,405	14,494	46,273	27	558,821	6,614	35,415	105,162	411,448	182
<b>Use of Nursing Facilities<sup>c</sup></b>												
Entire year	71	16	55	0	0	0	665	156	509	0	0	0
Part year	97	12	79	5	1	0	911	107	755	44	5	0
None	119,524	780	8,184	28,086	82,316	158	1,017,610	7,921	84,046	198,988	725,659	996
<b>Maintenance Assistance Status</b>												
Cash	41,454	777	7,552	16,065	17,060	0	367,483	7,938	77,573	126,362	155,610	0
Medically needy	0	0	0	0	0	0	0	0	0	0	0	0
Poverty related	65,734	0	0	9,905	55,671	158	537,346	0	0	56,613	479,737	996
Other/unknown	12,504	31	766	2,121	9,586	0	114,357	246	7,737	16,057	90,317	0
<b>Managed Care (MC) Status</b>												
Fee-for-service (FFS) all year	119,692	808	8,318	28,091	82,317	158	1,019,186	8,184	85,310	199,032	725,664	996
FFS part year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
FFS part year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, with Rx claims	0	0	0	0	0	0	0	0	0	0	0	0
MC all year, no Rx claims	0	0	0	0	0	0	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Table A.1 includes the beneficiaries represented by Cell J of Table 1. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

b. Medicaid basis of eligibility is classified as: aged, disabled, adults, and children. The disabled group includes beneficiaries of any age who were determined to be eligible because of disability or blindness. The children's group includes children receiving foster care and adoptive services. The total includes some beneficiaries with unknown basis of eligibility and some whose age categories are not consistent with basis of eligibility.

c. Please refer to footnote f of Table 1 for methodology used to determine nursing facility residence.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract; MC = managed care; Rx = pharmacy benefit.

APPENDIX TABLE A.2  
 MEDICAID BENEFICIARIES AND THEIR BENEFIT MONTHS WITH OR WITHOUT FEE-FOR-SERVICE PHARMACY BENEFITS<sup>a</sup>  
 NONDUAL BENEFICIARIES, ALASKA, 2005

	Beneficiaries and Benefit Months in Cell J of Table 1		Included in Cell K of Table 1		Excluded from Cell K of Table 1	
	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months	Number of Beneficiaries	Number of Benefit Months
<b>All</b>	<b>119,692</b>	<b>1,019,186</b>	<b>119,692</b>	<b>1,019,186</b>	<b>0</b>	<b>0</b>
Fee-for-service (FFS) all year	119,692	1,019,186	119,692	1,019,186	0	0
FFS part year, with Rx claims	0	0	0	0	0	0
FFS part year, with no Rx claims	0	0	0	0	0	0
Managed care (MC) all year, with Rx claims	0	0	0	0	0	0
MC all year, with no Rx claims	0	0	0	0	0	0

Source: Data for this table are from the MAX 2005 file for Alaska, released by CMS in 10/2008. This table was produced on 04/23/2009.

a. Benefit months are months during which beneficiaries had pharmacy benefit coverage.

Bene(s) = beneficiary (or beneficiaries); Bene Mo(s) = benefit month(s); CMS = Centers for Medicare & Medicaid Services; FFS = fee-for-service pharmacy benefit; MAX = Medicaid Analytic Extract;

MC = managed care; Rx = pharmacy benefit.

Nondual Beneficiaries